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Summary.-The murine dose of i.v. C. parvum (466 tLg) was compared with a single,
low, human-equivalent dose of 70 ,ug and with repeated weekly low doses. All treat-
ments increased the antibody titre against C. parvum (CP). However, repeated doses
stimulated a much higher titre than single doses. In all treated animals spleen
weight peaked at 2 weeks and then fell. A single low dose caused a 3-fold increase, a
single high dose or multiple low doses a 6-fold increase. Liver weight changes
followed a similar pattern. Hepatosplenomegaly was prolonged by multiple doses.
The effects of these treatments on Lewis tumour metastases were studied. A single
high dose and a single low dose onthe dayoftumour implantation (Day0) were equally
effective at inhibiting pulmonary metastases. Repeated low doses starting on Day 0
were no more effective than a single dose. The effect of CP on survival after primary-
tumour excision on Day 10 was observed. Low dose CP on Day7 doubled the harmonic
mean of survival time. Repeated doses were no more effective than a single dose.
Low-dose prophylaxis up to 2 weeks before tumour significantly inhibited meta-
stases. However, when repeated low-dose prophylaxis was combined with a single
low dose on Day 0, the anti-metastatic effect was abrogated. This neutralization ofthe
anti-metastatic effect of CP given on Day 0 was found to persist after a 13-week
treatment-free interval. Possible mechanisms for this phenomenon are discussed.
SYSTEMICALLY INJECTED C. parvum
(CP) has considerable anti-tumour prop-
erties in rodents (Halpern et al., 1966;
Woodruff & Boak, 1966; Smith & Scott,
1972; Proctor et al., 1973; Sadler & Castro,
1976). It is a potent stimulant of the
reticulo-endothelial system (RES) (Hal-
pern et al., 1963; Adlam & Scott, 1973)
and non-specific activation of macro-
phages is generally regarded as mediating
the anti-tumour effect (reviewed by Milas
& Scott, 1978). Cancer patients have been
treated with systemic CP (Israel et al.,
1975; Takita & Moayeri, 1976; Sarna et al.,
1977) but there is still no convincing
evidence of a beneficial antitumour re-
sponse. This difference between man and
rodents may be due to the dose of the
vaccine since, owing to the severity of the
side-effects, the human dose, when related
to surface area, is much lower than the
murine dose (Scott & Warner, 1976).
The aim ofthis study was to determine,
in mice, the best treatment regimen for
cancer using CP. We compared our usual
mouse dose (a single injection of 466 /tg)
with a single low, human-equivalent dose
(70 jig) and with repeated human-
equivalent doses.
MATERIALS AND METHODS
Mice.-Age-matched syngeneic female
C57BL mice (Olac) were used.
C. parvum.-A heat-killed suspension of
C. parvum (Wellcome, strain CN6134, 7 mg
dry weight/ml) was used. The high dose was
466 jLg and the low or human-equivalent dose
was 70 ,ug. This was calculated from our
clinical dose of 10 mg/M2 (Mitcheson &
Castro, 1978) relating the surface area of aH. D. MITCHESON, T. E. SADLER AND J. E. CASTRO
20g mouse to a 70kg human. Repeated treat-
ments were given weekly. The usual route of
administration was i.v. but in certain experi-
ments, designed to determine the best route,
i.p. and s.c. injections were used.
Toxicity.-Toxicity was monitored by ob-
serving animals for 4 h after injection and
recording the side-effects.
C. parvum antibody.-The serum was
stored at - 18°C and antibodies to CP
measured by passive agglutination. Doubling
dilutions ofserum were made with phosphate-
buffered saline to a total volume of 25 ,u in
each well of a microtitre plate. 25 ,ul of a
0-7mg/ml CP suspension was added to each
well. Positive and negative controls were in-
cluded in the test. The mixtures were incu-
bated for 2 h at 37°C and then at 4°C for 48 h.
Agglutination was observed and the antibody
titres expressed as powers of 2 (log2).
Organ weights and histology.-Four mice
were removed from each group at weekly
intervals, weighed, anaesthetized with ether
and exsanguinated from the heart. The liver,
spleen and thymus were removed and
immediately weighed. These organs, together
with lung and kidney, were fixed in formal
saline and histological appearances noted
after examination of sections stained with
haematoxylin and eosin.
Tumour.-Lewis lung carcinoma, which
originated spontaneously as a carcinoma of
the lung of a C57/BL mouse at the Wistar
Institute in 1951 (Sugiura & Stock, 1955)
was implanted s.c. as a 0Iml homogenate in
the lower flank. It is a rapidly growing
epidermoid carcinoma which, when implanted
s.c., metastasizes to the lungs (Simpson-
Herren et al., 1974). Cells are released from
the primary tumour 6 days after implantation
(James & Salsbury, 1974) and macroscopic
metastases are easily visible 21 days after
implantation.
Anti-tumour effects.-Two experimental
systems were used. In the first the tumour
was inoculated s.c. on Day 0 and the growth
ofthe primary tumour monitored by measur-
ing 2 diameters twice weekly and calculating
the mean diameter. The mice were killed on
Day 21 and macroscopic lung metastases
counted after staining the lungs by inflation
with Indian ink (Wexler, 1966). In the second
the tumour was implanted on Day 0 and sub-
sequently excised on Day 10 (Sadler &
Castro, 1976). The survival of the mice after
tumour excision was noted.
Statistics-Results were compared using
Student's t test. Group survival was expressed
as the harmonic mean survival time.
RESULTS
Biological effects
Toxicity.-Mice given a high dose of CP
became very ill for several hours with
erect fur, dyspnoea and a slow, staggering
gait. The low dose had little adverse effect.
All mice had a decrease in body weight
which lasted 2-3 weeks and this was
greater in mice receiving the larger dose.
Antibody titre.-Antibody titres ex-
pressed as the power of 2 are shown in
Fig. 1. Untreated mice had a low natural
titre. A single high dose increased this
titre progressively to 12 at 6 weeks and a
single dose to 11. Repeated low doses
stimulated a more rapid and pronounced
rise to 26.
Organ weights.-Spleen weight after CP
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FIG. 1. Antibody titres in C57BL mice at
weekly intervals after a single injection
of 70 ,ug C. parvum (0 .... *), of 466 ,ug
(0 0 *) and during the course of 6
weekly injections of 70,ug (0 --- 0). Each
point represents the mean from 4 mice and
the bar denotes s.e.
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FIG. 2. Spleen weiglhts in C57BL mice at
weekly intervals after a single injection of
70 ,ug C. parvum (0 .... *), of 466 ,ug
(0 0*) and (luring the course of 6
weekly injections of 70 ,ug (0 --- 0). Each
point represents the mean from 4 mice an(l
the bar denotes s.c.
is shown in Fig. 2. In all treated mice,
spleen weight peaked at 2 weeks and then
fell. A single low dose caused a 3-fold
increase in spleen weight. A single high
dose or multiple low doses caused a 6-fold
increase. This splenomegaly was prolonged
by multiple doses. Liver weight is shown
in Fig. 3 and the changes follow a similar
pattern to that of the spleen. Thymus
weight is shown in Fig. 4. Cortical atrophy
of the thymus occurred and followed an
inverse pattern to the alterations of spleen
and liver weights.
In mice receiving repeated injections,
liver and spleen weights were greatest 2
weeks after the first injection and then
fell, despite further injections. In a
separate experiment to determine when
the organs could be restimulated after an
initial low dose of CP, different groups of
mice received a second low dose 2, 4, 6, 8,
10 or 12 weeks later. Mice were killed 2
weeks after the second injection and their
liver and spleen weights compared with
organ weights 2 weeks after a first injec-
tion. The development of hepatospleno-
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FiG. :3. Liver weights in C57BL mice at
weekly intervals after a single injection
of 70 jug C. parvum (0 .... *), of 466 ,ug
(0O *) and during the course of 6
weekly injections of 70 ,ug (0 - - - 0).
Each point represents the mean from 4
mice and the bar denotes s.e.
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FIG. 4. Thiymus weights in C57BL mice at
weekly intervals after a single injection of
70 zg C. parvum (* . . -), of 466 ,Lg
(0 0*) and during the course of 6
wveekly injections of 70 jug (0 --- 0). Each
point represents the mean from 4 mice and
the bar denotes s.e.
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megaly was impaired in mice which
received a second injection 2 weeks after
the first, but was not impaired in those
receiving the second injection after 4 or
more weeks.
Histology.-A single high dose caused
thrombosis in hepatic, pulmonary and
splenic vessels, with consequent hepatic
necrosis. There was considerable recovery
after 4 weeks. A single low dose caused a
similar but much less severe pathology.
Multiple low doses had the same effects as
a single low dose and no fresh pathology
occurred after the second or subsequent
injections. Considerable recovery was ob-
served 4 weeks after the first injection.
Anti-tumour effects
Single doses.-Table I shows the effect
on tumour metastasis of various single
doses of CP given on the same day as
Lewis tumour (Day 0). A single high dose
(466 jtg) and a single human-equivalent
dose (70 lg) were equally effective in sig-
nificantly reducing pulmonary metastasis.
The lowest dose to inhibit tumour meta-
stasis was 35 ,tg.
TABLE I.-The effect on Lewis tumour
metastasis of various i.v. doses of CP on
Day 0
Dose of
CP on
Day 0
(lg)
466
140
70
35
17-5
No. of
mice
7
9
8
9
8
7
Mean
no. of
pulmonary
metastases
+s.d.
16+13
3+6
1+1
3+3
1+1
12+14
p
(vs control)
<0-002
<0-01
< 0-01
< 0-01
not sig.
TABLE II.-The effect on primary Lewis
tumour and its metastases of a single i.v.
low dose of 70 ,ug CP and repeated low
doses
Treat-
ment
on
Days
0
0, 7
0,7, 14
No.
of
mice
15
16
17
17
Mean
diam
(mm) Mean
of no. of
primary pul-
tumour P monary
on (vs. metas-
Day 21 con- tases
+ s.d. trol) ± s.d.
23-9+4-4 20+ 14
19-8+2-9 <0-01 4+4
19-6+2-8 <0 01 3+3
18-1+2-4 <0001 2+2
p
(v8.
con-
trol)
< 0-001
<0-001
<0-001
group are shown in Table II. All CP treat-
ments inhibited the growth of the pul-
monary tumour and significantly reduced
the number of pulmonary metastases.
Repeated doses were no more effective
than a single dose.
Survival: single vs repeated doses.-In
this experiment the tumour was inocu-
lated on Day 0 and excised on Day 10. The
control group received no other treatment.
Mice received low dose CP as a single
injection on Day 7 or Day 13, or repeated
weekly injections starting on Day 7 or
Day 13.
TABLE III.-The effect of CP regimens on
harmonic mean survival after tumour
excision on Day 10
Treatment No. of
on Days mice
10
7 9
7,14,21,28,35,42 9
13 10
13,20,27 10
Harmonic mean
survival time
after tumour
excision (days)
11*0
21-7
22-4
8-5
13-2
Single vs repeated doses.-The anti-
metastatic effect of a single low dose
(70 jug) given on the day of tumour im-
plantation was compared with that of
repeated low doses. Two groups of mice
received repeated doses: one on Days 0
and 7, and the other on Days 0, 7 and 14.
The animals were killed on Day 21. The
primary tumour growth and the mean
number of pulmonary metastases for each
Table III shows the harmonic mean
survival time after tumour excision. The
control group had a harmonic mean
survival of 11-0 days. Survival was twice
as long in those groups that received CP
on Day 7, either as a single dose or as
repeated doses starting on that day.
Treatment on Day 13, either as a single
dose or as repeated doses starting on that
day, was ineffective.
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TABLE IV.-The effect on primary Lewis
tumour and its metastases ofprophylactic
single i.v. injections of CP
No.
On of
Day mice
10
0 8
-7 8
-14 9
-21 9
-21 10
Mean
diam.
(mm)
of
primary
tumour
on
Day 21
+s.d.
19-7+ 2-1
16-5_ 2-6
14-9+2-4
19-0+2-4
17-8+3-3
19-0+_19
Mean
no. of
pul-
P monary
(cf. metas-
con- tases
trol) ± s.d.
11+ 12
<0-02 1+1
< 0-001 1 1
3+5
6+7
-5+5
p
(cf)
con-
trol)
<0-1
<0-1
<0-1
Single-dose prophylaxis.-CP was given
at intervals up to 3 weeks before the
tumour (Table IV). Treatment one week
before tumour significantly inhibited
primary tumour growth and significantly
reduced the number of pulmonary metas-
tases and was as effective as treatment on
the day of tumour implantation. Earlier
pre-treatment did not inhibit primary
tumour growth, though the number of
pulmonary metastases was significantly
reduced by treatment 2 weeks before
tumour. Treatment 3 weeks before tumour
was ineffective.
Combination oflow-doseprophylaxis with
a further dose at tumour inoculation.-
Repeated low-dose prophylaxis was com-
bined with an additional low dose on
Day 0 (Table V). Three groups received
No.
CP on of
Day mice
14
14
,0 20
4,-7,0 16
Mean
diam.
(mm) of
primary
tumour
on
Day 21
> +s.d.
24-8 + 2-8
23-7+2-5
25-7+ 19
25-7+ 17
p
(cf.
con-
trol)
18 24-8+2-0
prophylaxis, the first group on Days - 21,
-14 and - 7, the second on Days - 14 and
- 7 and the third on Day - 7. A separate
group received CP only on Day 0. The
growth ofthe primary tumour was similar
in all groups. The number of pulmonary
metastases was significantly reduced in
mice receiving CP only on Day 0. How-
ever, in mice which received prophylaxis
and CP on Day 0 there was no inhibition
ofmetastases.
Low-dose prophylaxis followed by a 13-
week treatment-free interval.-The pre-
ceding experiment was repeated leaving a
13-week treatment-free interval between
prophylaxis and tumour implantation
(Table VI). A similar result occurred; the
TABLE VI.-The effect on primary Lewis
tumour and its metastases of low dose
i.v. CP prophylaxis, followed by a
13-week treatment-free interval, before
tumour inoculation accompanied by a
further low dose
0
-9
-9
N
CP on c
Day mi
0, 0
7,-90, 0
-104, -97,
-90, 0
Mean
diam.
(mm) of
primary
Co. tumour
f on
ice Day 21
9 19-5+2-0
9 18-8+1-8
7 17-7+2-4
8 20-1+1-5
7 18-9+1-5
Mean
no. of
pul-
P monary P
(cf. metas- (cf.
con- tases con-
trol +s.d. trol)
22+10
-6+4 <0-001
- 16+ 21
26 +18
- 16+11
irimtary Lewis
s of low dose anti-metastatic effect of a single low dose
xxis combined at the time of tumour implantation was
Day 0 abrogated by prophylaxis.
Route of administration. - Different
Mean routes of administration were compared
no. of using a single high dose. Hepatospleno-
mpnary p megaly developed more rapidly after i.v.
metas- (cf. than after i.p. injection, reaching a maxi-
tases con- mum 12 days after i.v. and 14 days after +s.d. trol) i.p. administration. Lewis tumour metas-
44+13
16+12 <0-001 tases were equally inhibited by i.v. or
39+ 14 i.p. CP. Subcutaneous CP at this dose did
53+22 not cause hepatosplenomegaly or inhibit
44+ 14 the tumour.
Dose
of
CP
(Ktg)
70
70
70
70
466
TABLE V.-The effect on p
tumour and its metastas&
(70 ,ug) i.V. CP prophylc
with afurther low dose on A
0
-7!
-1'
-21, -14,
-7, 0
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DISCUSSION
Most studies on the effects of CP in
experimental animals have used a single
high dose ofthe vaccine; in mouse studies
the average dose range has been 75-100
mg/M2 (reviewed by Scott, 1974a). The
human dose is much lower, 2-10 mg/M2
(Thatcher & Crowther, 1978; Cederholm-
Williams et al., 1978; Mitcheson & Castro,
1978) but repeated treatments are often
given. At this Institute we give patients
with cancer CP at a dose of 10 mg/Mi2,
repeating the treatment at monthly inter-
vals to a total of 6 treatments. This study
was designed to determine, in mice, the
best treatment regimen for cancer using
CP, comparing the traditional mouse dose
with a single low, human-equivalent dose
(70 pg) and with repeated human-
equivalent doses.
In C57/BL mice a single high dose
caused considerable toxic side-effects, in-
cluding thrombosis (Lampert et al., 1977).
A second high dose caused an anaphylac-
tic-type reaction and death (Mitcheson, in
preparation). Low doses were much better
tolerated, and could be repeated. Both
high and low doses caused hepatospleno-
megaly, but thrombosis and subsequent
infarction and necrosis were much less
severe in animals receiving a low dose.
Interestingly, repeated doses did not
cause fresh pathology.
CP's antitumour action is attributed to
non-specific activation of macrophages
(reviewed in Milas & Scott, 1978). RES
stimulation can be measured by weight
increases ofliver and spleen or by stimula-
tion of phagocytic activity, and these can
be used as indices of anti-tumour activity
(Adlam & Scott, 1973; McBride et al.,
1975). On this basis we predicted that
repeated low doses would give the best
anti-tumour effect, but this was not sup-
ported by our subsequent findings.
The effect of various single doses of CP
on Lewis tumour metastases was deter-
mined. The human-equivalent dose was as
effective as larger doses and significantly
reduced pulmonary metastases. (This ex-
cluded the possibility of any summation
of effect due to giving sub-optimal doses.)
A single low dose was compared with
repeated low doses. Both treatments pro-
longed survival but, again, repeated doses
did not confer any extra protection. This
supports Scott's observation (1974b) that
multiple doses of CP were no more
effective than a single dose. However,
Fisher et al. (1975) found that repeated
i.p. injections of a therapeutic dose of
CP inhibited primary tumour growth
more than a single injection and Milas et
al. (197.5) reported that the antitumour
protection afforded by repeated sub-
optimal doses of CP in mice was greater
than that ofthe total dose given as a single
i.v. injection.
CP administered up to 2 weeks before
tumour implantation inhibited pulmonary
metastasis as effectively as treatment on
the day of tumour implantation. Pre-
treatment earlier than 2 weeks was in-
effective. However, when repeated low-
dose prophylaxis was combined with a
therapeutic low dose on the day oftumour
implantation, the anti-metastatic action
was completely neutralized. A similar
finding has been reported after repeated
prophylaxis with C. granulo8um (Milas et
al., 1975). In contrast, Scott & Warner
(1976) found resistance to tumour-cell
challenge in mice that had received 14
weekly prophylactic injections of a
"human-equivalent" dose of CP (5.25
mg/M2). There are several mechanisms by
which the anti-metastatic action of CP
could be neutralized:
(1) The RES stimulated by CP may
become refractory to further stimulation.
This is suggested by the impaired develop-
ment of hepatosplenomegaly in mice
which received a second injection of CP
2 weeks after the first and would explain
why repeated low doses did not maintain
maximum hepatosplenomegaly. However,
this "refractory period" lasts less than 4
weeks after a single injection and neutral-
ization of the anti-metastatic effect still
occurred after a 13-week treatment-free
interval.
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(2) Circulating immune complexes
(CIC) can block cell-mediated immunity
(Baldwin & Robins, 1976) and large
quantities can saturate the RES (Mannik
et al., 1974). We have found that repeated
doses of CP caused a significant and pro-
longed increase in CIC in mice (Mitcheson,
in preparation).
(3) The high titre of anti-CP antibody
produced after repeated doses, or indeed,
the injected CP itself, may in some way
neutralize the anti-metastatic effect.
(4) CP may promote suppressor-cell
activity (Mathe et al., 1978).
Repeated human-equivalent doses ofCP
in mice have less adverse side-effects and
cause most RES change. They raise very
high antibody titres and increase circula-
ting immune complexes. However, their
anti-tumour effectisnogreaterthanthat of
a single "human-equivalent" dose and, in-
deed, repeated prophylaxis neutralizes the
protective action. We conclude that in
our mouse system the best cancer treat-
ment with CP is a single human-equivalent
dose (70 pg) administered i.v. This finding
may have clinical implications for C.
parvum therapy.
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